Sugi Predict

Sugi Predict / Compounds / SCHEMBL440599

SCHEMBL440599

SCHEMBL440599

Nc1ncnc2c1nc(Br)n2[C@H]1C[C@H](O)[C@@H](CO)O1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 5/20 0.64
▸ ADORA3 P0DMS8 4/20 0.64
▸ NADK O95544 2/20 0.54
▸ HSPA5 P11021 2/20 0.53
▸ HSPA8 P11142 2/20 0.53
▸ ADORA1 P30542 4/20 0.51
▸ ADORA2B P29275 3/20 0.51
▸ HIF1A Q16665 1/20 0.50
▸ RXFP1 Q9HBX9 2/20 0.49
▸ LMNA P02545 2/20 0.49
▸ TP53 P04637 2/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ PNP P00491 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ PDE4D Q08499 1/20 0.49
▸ PDE3A Q14432 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.47
▸ GAPDH P04406 1/20 0.47
▸ TRPM2 O94759 1/20 0.47
▸ HBB P68871 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29673055 1.00 ADORA2A (0.64) ADORA2AADORA3NADKHSPA5HSPA8
SCHEMBL659995 1.00 ADORA2A (0.64) ADORA2AADORA3NADKHSPA5HSPA8
SCHEMBL20419331 1.00 ADORA2A (0.64) ADORA2AADORA3NADKHSPA5HSPA8
SCHEMBL29283551 1.00 ADORA2A (0.64) ADORA2AADORA3NADKHSPA5HSPA8
SCHEMBL14253676 1.00 ADORA2A (0.64) ADORA2AADORA3NADKHSPA5HSPA8
SCHEMBL30366664 1.00 ADORA2A (0.64) ADORA2AADORA3NADKHSPA5HSPA8
SCHEMBL24420987 1.00 ADORA2A (0.64) ADORA2AADORA3NADKHSPA5HSPA8
Phosphoric Acid SCHEMBL16208889 0.95 ADORA3 (0.59) ADORA2AADORA3NADKHSPA5HSPA8
SCHEMBL7047708 0.89 ADORA3 (0.54) ADORA2AADORA3NADKHSPA5HSPA8
SCHEMBL658005 0.88 ADORA3 (0.67) ADORA2AADORA3HSPA5HSPA8HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024077351-A1 MODIFIED OLIGONUCLEOTIDES Pharmorage Pty Limited (AU) 2024-04-18 — — WO claimed
CN-112209930-A Istradefylline derivative and preparation method and application thereof 山东新华制药股份有限公司 2021-01-12 — — CN claimed
WO-2012164484-A1 ADENOSINE OR DEOXYADENOSINE DERIVATIVES MODIFIED AT POSITION 8 AND A METHOD OF SYNTHESIS THEREOF CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 2012-12-06 — — WO claimed
US-20040110718-A1 Anti-HCV nucleoside derivatives DEVOS RENE (GB) 2004-06-10 — — US claimed
CN-1466591-A Nucleoside derivatives - 2004-01-07 — — CN claimed
US-20030008841-A1 Anti-HCV nucleoside derivatives F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) 2003-01-09 — — US claimed
WO-2026106815-A1 Z-INDUCING CHIMERA COMPOSITION RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2026-05-21 — — WO disclosed
US-12584168-B2 Sample preparation method OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-03-24 — — US disclosed
US-20260066042-A1 METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS OPENTRONS LABWORKS INC (US) 2026-03-05 — — US disclosed
US-20250313889-A1 SAMPLE PREPARATION METHOD OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2025-10-09 — — US disclosed
EP-4601656-A1 MODIFIED OLIGONUCLEOTIDES Pharmorage Pty Limited (AU) 2025-08-20 — — EP disclosed
US-20250135036-A1 COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2025-05-01 — — US disclosed
EP-4404942-A2 COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF Wave Life Sciences Ltd. (SG) 2024-07-31 — — EP disclosed
EP-0558634-A4 TRIPLEX-FORMING OLIGOMERS CONTAINING MODIFIED BASES GILEAD SCIENCES INC (US) 1995-06-28 — — EP disclosed
WO-1995008003-A1 SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX UNIVERSITY RESEARCH CORPORATION (US) 1995-03-23 — — WO disclosed
WO-1994021822-A1 DNA SEQUENCING BY MASS SPECTROMETRY VIA EXONUCLEASE DEGRADATION SEQUENOM, INC. (US) 1994-09-29 — — WO disclosed
WO-1994016101-A2 DNA SEQUENCING BY MASS SPECTROMETRY KOESTER HUBERT (US) 1994-07-21 — — WO disclosed
EP-0558634-A1 TRIPLEX-FORMING OLIGOMERS CONTAINING MODIFIED BASES GILEAD SCIENCES, INC. (US) 1993-09-08 — — EP disclosed
WO-1992009705-A1 TRIPLEX-FORMING OLIGOMERS CONTAINING MODIFIED BASES GILEAD SCIENCES, INC. (US) 1992-06-11 — — WO disclosed
US-5013829-A Stable congener of 2',3'-dideoxyadenosine UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 1991-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12584168-B2 Sample preparation method POLN, POLRMT, POLM ADORA2A 1754/4885ADORA3 1197/4885NADK 1715/4885
US-20030008841-A1 Anti-HCV nucleoside derivatives PNP, HAVCR2, NUDT14 ADORA2A 70/4885ADORA3 102/4885NADK 134/4885
US-20040110718-A1 Anti-HCV nucleoside derivatives PNP, HAVCR2, NUDT14 ADORA2A 70/4885ADORA3 102/4885NADK 134/4885
US-20260066042-A1 METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS POLRMT, POLL, SARS1 ADORA2A 2575/4885ADORA3 1734/4885NADK 4349/4885
US-20250135036-A1 COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF MECP2, ADAR, NSUN2 ADORA2A 151/4885ADORA3 300/4885NADK 3139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.